Anthera Pharmaceuticals, Inc. (ANTH) Stock Price & Analysis
Anthera Pharmaceuticals, Inc. (ANTH) closed at USD 0 on Thursday, October 22, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0; the Oct 22, 2026 session ranged USD 0–0 on volume of 23,894 shares. Market capitalization is $3,665, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, retrieved October 24, 2026 at 02:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ANTH.md
Key facts (ANTH)
- Analysts: None.
- Total return with dividends: 1Y +40.0% vs S&P 500 +13.4%; 5Y +40.0% vs S&P 500 +76.9%.
Analysts (ANTH)
Consensus None.
Total return (dividends reinvested) (ANTH)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +40.0% | +40.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +40.3% | +7.0% |
| Volatility (annualized) | 508.8% | 267.5% |
| Max drawdown | -95.0% (May 2026→May 2026) | -95.0% (Dec 2021→Jul 2022) |
ANTH analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter (ends Sep 2018) | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2018) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 02:20 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 23,894 shares |
| Market Cap | $3,665 |
| Exchange | PNK |
Technical Analysis (ANTH)
Nexqual's technical model rates ANTH "BUY" based on 4 bullish and 2 bearish signals across 126 daily candles, as of October 24, 2026 at 02:20 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (ANTH)
Wall Street analysts rate ANTH "None", per Nexqual as of October 24, 2026 at 02:20 UTC.
| Consensus Rating | None |
|---|
Earnings (ANTH)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2018-03-31 | USD -0.42 vs est -0.54 ▲ beat |
| 2017-12-31 | USD -0.7 vs est -0.68 ▼ miss |
| 2017-09-30 | USD -0.73 vs est -0.9 ▲ beat |
| 2017-06-30 | USD -0.86 vs est -1.63 ▲ beat |
Source: Nexqual, October 24, 2026 at 02:20 UTC.
Financials & Fundamentals (ANTH)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -568.85% |
| Current Ratio | 3.3 |
| Total Cash | $8.09M |
| Total Debt | $0 |
Source: Nexqual, October 24, 2026 at 02:20 UTC.
Financial Health Score (ANTH)
Nexqual rates Anthera Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 02:20 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $8M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$32M (TTM) |
| Efficiency | Critical — ROE -569%, ROA -142.0% |
Ownership (ANTH)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 26.18M |
| Float | 26.13M |
| Short % of Float | +8.41% |
Source: Nexqual, October 24, 2026 at 02:20 UTC.
Leadership (ANTH)
Anthera Pharmaceuticals, Inc. is led by Paul F. Truex, Executive Chairman, per Nexqual as of October 24, 2026 at 02:20 UTC.
| Executive Chairman | Paul F. Truex |
|---|---|
| Senior Vice President of Global Regulatory Affairs and Compliance | Paul Adams |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 303.53 | ▼ 1.39% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.27 | ▼ 1.79% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.09 | ▼ 0.35% |
| PRAX | Praxis Precision Medicines, Inc | USD 252.96 | ▼ 2.3% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.93 | ▼ 2.23% |
| AXSM | Axsome Therapeutics, Inc. | USD 145.04 | ▼ 7.07% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 02:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt